Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

To assess the effectiveness and toxicity of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice, as well as predictive factors of effectiveness. This was a retrospective multicenter study in patients with mCRC who received regorafenib from November 2013 to M...

Full description

Saved in:

Bibliographic Details
Published in:	Oncology (Williston Park, N.Y.) Vol. 36; no. 12; p. 732
Main Authors:	Calvo-García, Alberto, Abánades, María Pérez, Ruíz-García, Silvia, Román, Ana Beatriz Fernández, Fernández, Javier Letellez, García, Beatriz Candel, Terciado, Carlos Hernández, Álvarez, Raquel De Santiago, Solis, Rebeca Mondéjar, Marin, Berta Hernández, Diez, Patricia Toquero, Baladrón, Alberto Morell, Bosch, Ramón Colomer
Format:	Journal Article
Language:	English
Published:	United States 01-12-2022
Subjects:	Colonic Neoplasms Colorectal Neoplasms - pathology Female Humans Liver Neoplasms - secondary Male Middle Aged Phenylurea Compounds - adverse effects Rectal Neoplasms Routinely Collected Health Data
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To assess the effectiveness and toxicity of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice, as well as predictive factors of effectiveness. This was a retrospective multicenter study in patients with mCRC who received regorafenib from November 2013 to May 2020. Effectiveness was evaluated by overall survival (OS) and progression-free survival (PFS) using the Kaplan-Meier method. Cox regression was performed to determine survival predictors. Ninety patients were enrolled (median age, 64.3 years). Fifty-two patients (57.8%) were male, and 57 (63.3%) had an ECOG performance status (PS) of 0 to 1. Median follow-up was 2.80 months. Median OS was 8.03 months (95% CI, 5.90-10.17), and median PFS was 2.90 months (95% CI, 2.59-3.21). Eighty-eight patients (97.8%) experienced drug-related adverse events. The most frequent were fatigue in 66 patients (73.3%), followed by palmar-plantar erythrodysesthesia in 40 (44.4%). Low liver tumor burden score (LTBS) and good ECOG PS were independent OS predictive factors. Patients taking regorafenib had OS and PFS rates similar to those reported in previous randomized trials; the agent had a poor toxicity profile. We identified low LTBS and good ECOG PS as possible predictive factors of better OS, useful in selecting patients with mCRC who might benefit from regorafenib.
ISSN:	0890-9091
DOI:	10.46883/2022.25920981